Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04562025
Other study ID # 20200915HMD
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date September 25, 2020
Est. completion date December 31, 2021

Study information

Verified date September 2020
Source Renmin Hospital of Wuhan University
Contact Huiming Wang, MD
Phone 18971563100
Email rm000301@whu.edu.cn
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Diabetic nephropathy (DN) is one of the most serious complications of diabetes and the leading cause of end-stage chronic kidney disease. DN is a refractory disease with low awareness, high incidence, and high disability. The incidence of DN can reach 30 to 40% after 20 years of diabetes, of which 5~10% of patients will progress to end-stage renal disease, and epidemiological surveys predict that by 2030, DN will become the seventh leading cause of death in the world. Currently, there are no effective drugs for treating DN. This clinical trial is to inspect the safety and efficiency of human umbilical cord mesenchymal stem cells (UC-MSCs) therapy for patients with DN.


Description:

Diabetic nephropathy (DN) is one of the most important microvascular complications of diabetes. It is a persistent and refractory disease. There is currently a lack of effective clinical treatments for DN. The basic pathological processes of DN are renal tissue cell damage, apoptosis and continuous increase of inflammatory cytokines induced by early high glucose, which gradually leads to glomerular sclerosis and renal fibrosis.

Human umbilical cord mesenchymal stem cells (UC-MSCs), as the "youngest" adult stem cells, have powerful anti-inflammatory functions, stronger differentiation potential, and good safety. They are ideal seed cells for the treatment of DN. At present, studies on a variety of animal models of DN have shown that mesenchymal stem cell transplantation can delay the progression of DN and have a certain repair effect on damaged kidney tissue and renal function. Our previous preclinical study showed that UC-MSCs effectively improved the renal function, inhibited inflammation and fibrosis, and prevented its progression in a rat model of diabetes-induced chronic renal injury. Some autologous or allogeneic mesenchymal stem cells have been carried out abroad treatment of chronic kidney disease caused by various reasons, including clinical trials of DN, phase I/II test results did not show obvious adverse reactions related to stem cell therapy, and can improve the patient's renal function and quality of life to a certain extent.

The purpose of this study is to investigate efficiency and safety of UC-MSCs in treating DN patients. This trial will recruit 38 patients. 19 patients received the treatment of conventional treatment + equal volume normal saline containing 1% human albumin (placebo group) were used as control group; conventional treatment + 1*10E6 UC-MSCs/kg body weight (experimental group) for intravenous infusion (once a week, 3 times in total) to treat 19 patients with DN (by unified standard inclusion), and subjects will be followed a total of 48 weeks from time of initial cell treatment.


Recruitment information / eligibility

Status Recruiting
Enrollment 38
Est. completion date December 31, 2021
Est. primary completion date September 25, 2021
Accepts healthy volunteers No
Gender All
Age group 30 Years to 65 Years
Eligibility Inclusion Criteria:

1. Type 2 diabetes mellitus, course 5-15 years;

2. Age 30-65 years old, no gender limit;

3. Accompanied by proteinuria, urine albumin/creatinine ratio (UACR)>300mg/g or 24h urine protein quantitative>0.5g/24h;

4. eGFR is between 30-60 ml/min/1.732 m2;

5. Take RASI-based antihypertensive drugs to control blood pressure and blood pressure meets the following standards: systolic blood pressure <150mmHg, and diastolic blood pressure <100mmHg;

6. Blood lipids and blood uric acid are controlled at appropriate levels;

7. The pathological diagnosis of kidney biopsy is diabetic nephropathy;

8. Patients who have good compliance, signed informed consent, and can complete the entire trial treatment and follow-up plan according to the research plan;

9. No exclusion criteria are positive.

Exclusion Criteria:

1. Have a history of primary glomerulonephritis, lupus nephritis, ANCA-related small vasculitis, renal damage, allergic purpura nephritis, hepatitis B-related nephritis;

2. Poor blood glucose control: HbA1c =9% of patients or 2h postprandial blood glucose> 22mmol/L;

3. Active liver disease or liver function test results are obviously abnormal (ALT or AST = 2 times the upper limit of normal);

4. White blood cell count<3.0×10E9/L, hemoglobin<80 g/L, platelet count<100×10E9/L or suffering from other blood system diseases (severe anemia, idiopathic thrombocytopenic purpura, splenomegaly, Patients with coagulopathy, etc.);

5. Severe and unstable cardiovascular and cerebrovascular diseases (unstable angina pectoris, coronary artery disease, cerebrovascular disease, transient ischemic attack, congestive heart failure, etc.), acute and uncontrollable disease, still unable to effectively control severe hypertension (blood pressure> 160/100 mmHg) after treatment or organ transplant patients;

6. The dose of antihypertensive drugs and/or hypoglycemic drugs used in the past 3 months has increased significantly than before;

7. Uncontrolled infection;

8. Suffer from tumor or abnormal level of tumor markers;

9. Suffer from blood-borne diseases (for example, HIV, syphilis, hepatitis B and hepatitis C);

10. Possibility of pregnancy, preparation for pregnancy or breastfeeding;

11. Receive immunosuppressive treatment;

12. Have a history of allergies, especially those who are allergic to human albumin;

13. Suffer from mental illness, which will affect their voluntariness, decision-making ability and communication ability;

14. A history of alcohol abuse or a known history of drug abuse in the last 2 years;

15. Participate in another clinical trial within the last 3 months;

16. Poor compliance, unable to complete the entire study;

17. The researcher diagnosed that the patient is not suitable for this study

Study Design


Intervention

Drug:
UC-MSCs
3 times of UC-MSCs (1*10E6 UC-MSCs/kg body weight/100mL saline containing 1% human albumin intravenously at week 1,week 2, week 3).
Placebo
3 times of cell-free stem cell suspension (saline containing 1% human albumin/100mL intravenously at week 1, week 2, week 3).

Locations

Country Name City State
China Renmin Hospital of Wuhan university Wuhan Hubei China

Sponsors (2)

Lead Sponsor Collaborator
Renmin Hospital of Wuhan University Wuhan Hamilton Biotechnology Co., Ltd

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Adverse Events The number of Adverse Events associated with UC-MSCs intervention per treatment arm From Baseline (0 W) to 48 weeks after treatment
Primary Adverse Events The percentage of Adverse Events associated with UC-MSCs intervention per treatment arm From Baseline (0 W) to 48 weeks after treatment
Secondary Kidney function Change in estimated glomerular filtration rate (eGFR) from baseline. From Baseline (0 W) to 48 weeks after treatment
Secondary Kidney function Change in 24-hour urinary protein quantification from baseline. From Baseline (0 W) to 48 weeks after treatment
Secondary Kidney function Change in urinary albumin/creatinine ratio from baseline From Baseline (0 W) to 48 weeks after treatment
Secondary Kidney function The proportion of subjects in both groups who progressed to end-stage renal disease (ESRD) or doubled their serum creatinine. From Baseline (0 W) to 48 weeks after treatment
Secondary SF-36 (The MOS item short from health survey) The MOS item short from health survey, SF-36 and changes per visit. As a concise health questionnaire, SF-36 comprehensively summarizes the quality of life of the surveyed from 8 aspects: physical functioning, role-physical, bodily pain, general health, vitality, social functioning, role emotional and mental health. Higher scores mean a better outcome. From Baseline (0 W) to 48 weeks after treatment
Secondary Change in HbA1c Change in Glycosylated Hemoglobin (HbA1c) from baseline. From Baseline (0 W) to 48 weeks after treatment
See also
  Status Clinical Trial Phase
Not yet recruiting NCT03658317 - Renal Resisitive Index as an Indicator of the Progression of Diabetic Nephropathy N/A
Recruiting NCT02501772 - The Evaluation of Effect of Sanyinjiao (SP6) Acupressure on Early Diabetic Nephropathy N/A
Completed NCT02276196 - Effect of LIXIsenatide on the Renal System Phase 4
Completed NCT02829177 - Microalbuminuria and Allopurinol in Type 1 Diabetes Phase 4
Completed NCT02251067 - Phase 2 Study to Evaluate Safety & Efficacy of VPI-2690B in Diabetic Nephropathy Patients Phase 2
Completed NCT01440257 - A Study to Evaluate the Effect of CCX140-B on Urinary Albumin Excretion in Subjects With Type 2 Diabetes and Albuminuria Phase 2
Active, not recruiting NCT01273675 - An Investigation on the Effect of Candesartan on Early Diabetic Nephropathy N/A
Terminated NCT01129557 - Aldosterone Breakthrough During Diovan, Tekturna, and Combination Therapy in Patients With Proteinuric Kidney Disease Phase 4
Completed NCT00317954 - Spironolactone in Diabetic Nephropathy Phase 4
Active, not recruiting NCT02237352 - Mechanisms of Diabetic Nephropathy in Ecuador
Not yet recruiting NCT05061459 - The Expression of circANKRD36 as a New Biomarker of Diabetic Nephropathy
Completed NCT01935167 - To Determine the Efficacy and Safety of DW1029M on Microalbuminuria in Patients With Diabetic Nephropathy Phase 2
Recruiting NCT01673204 - Clinical Trial Technology Development for the Validation of Surrogate Prognostic Markers in Patients With Diabetic Nephropathy Phase 4
Completed NCT01726816 - Efficacy and Safety Study of Probucol in Patients With Diabetic Nephropathy Phase 2
Recruiting NCT01458158 - Matrix Metalloproteinases in Atherosclerosis of Chronic Kidney Disease N/A
Completed NCT01476501 - Vitamin D Supplementation in Diabetic Nephropathy Phase 2
Completed NCT01447147 - A Study to Evaluate the Safety and Efficacy of CCX140-B in Subjects With Diabetic Nephropathy Phase 2
Completed NCT01003236 - Evaluating the Renoprotective Effect of Milk Thistle Extract on Patients With Type II Diabetic Nephropathy Phase 2
Completed NCT00535925 - Nephropathy In Type 2 Diabetes and Cardio-renal Events Phase 4
Completed NCT00097955 - Safety and Efficacy of Aliskiren When Added to Standardized Losartan and Optimal Antihypertensive Therapy in Patients With Hypertension, Type 2 Diabetes and Proteinuria Phase 2